Gene therapy company Sio to liquidate

Today's Big News

Dec 15, 2022

Horizon CEO Walbert in line for major payday after Amgen sale 


Gates, Bezos back $75M round for Synchron’s drill-free brain-computer interface implant  


Sio confirms gene therapy company will be liquidated after tough year  


CMS: National health spending grew by 2.7% in 2021 as the COVID-19 pandemic's effects linger

 

Featured

Horizon CEO Walbert in line for major payday after Amgen sale

Horizon Therapeutics CEO Tim Walbert has made routine appearances in rankings of the biopharma industry's best-paid executives, and he's set to collect once again with his company's sale to Amgen.
 

Top Stories

Gates, Bezos back $75M round for Synchron’s drill-free brain-computer interface implant

After announcing that it had implanted its brain-computer interface in its first U.S. paralysis patient earlier this year, Synchron has raised $75 million to take its mind-reading tech to the next level.

Sio confirms gene therapy company will be liquidated after tough year

Sio Gene Therapies has kept its head down since dropping its final two assets and most staff in April, but the company has finally confirmed that it’s shutting up shop for good.

CMS: National health spending grew by 2.7% in 2021 as the COVID-19 pandemic's effects linger

Health spending grew by 2.7% in 2021, reaching $4.3 trillion, according to new data from the Centers for Medicare & Medicaid Services.

Healthcare sector adds jobs through fall but still faces elevated quit rates: Fitch Ratings

Hospitals added a net 11,000 jobs to their payrolls in November, but a hiring slowdown, low unemployment, lingering high quit rates and an uptick in respiratory illnesses all threaten continued gains.

AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer

The FDA has delayed its target date for its decision on AstraZeneca and Merck's Lynparza in metastatic castration-resistant prostate cancer (mCRPC). The agency has pushed back the decision date by three months to “provide further time for the full review of the submission,” Merck said.

Winter is coming: White House restarts free COVID test shipments

Limited to four tests per household, the potential stocking stuffers will begin shipping through the mail December 19.

45 days later, BioCryst abandons another program, citing stiff competition

Last month, BioCryst trimmed down its pipeline to two drugs in complement-mediated diseases: BCX9930 and BCX10013. Fast forward 45 days and BCX9930 is headed to the garbage can, too.

Rural hospital closures have spillover effects for other nearby facilities, researchers warn

Two-thirds of the 53 rural hospital closures reviewed by researchers occurred within the Southern U.S. with just over a fifth located in Appalachia. Shutdowns were associated with significant increases in average emergency department and inpatient volumes among surrounding facilities.

Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID

Axcella is reducing its workforce by 85% as it drops its nonalcoholic fatty liver disease program and focuses its remaining resources on its long COVID candidate.

Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access

The Interfaith Center on Corporate Responsibility, a group of activist stakeholders, asked top drugmakers to consider patient access when they develop patent strategies.

Galderma expands its scope at art festival

The relationship between art, beauty and self-expression is a close one. Galderma continues to foster those ties as the exclusive aesthetic injectables sponsor of Scope Miami Beach, a showcase for emerging contemporary art.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Alzheimer's developments, plus this week's headlines

This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks.

 

Resources

Video

Discover the future of mAb manufacturing

Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights.
Whitepaper

Enhance the cost-effectiveness of your chemical supply chain

Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific.
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Webinar

Webinar: Writing the Future of Antibody Discovery Solutions

Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.

Executive Summary

Scale-Up Strategies for Late-Stage Cell Therapies

Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions.

Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Whitepaper

Linear Compression vs. Parallel Processing: Speeding Biologics Through Development and Into Clinical Trials

Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
 

Industry Events

 

Upcoming Fierce Events

10
Jan
San Francisco, CA
17-19
Jan
Virtual Event
27-28
Feb
Arlington, VA
14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL

View all events